Is atherosclerosis an autoimmune disease?
Autoimmunity Reviews · 2026-11 · 104232
DOI: 10.1016/j.autrev.2026.104232 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Autoimmunity Reviews, 2026-11. Verfasst von Haralampos M Moutsopoulos und 1 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Athens, Section of Sciences, Chair of Medicine-Immunology, Athens, Greece. Die Arbeit nennt 97 Literaturangaben.
Abstract (Originalsprache)
Atherosclerosis was traditionally viewed as a lipid-storage disorder driven by dyslipidemia and vascular injury. However, accumulating evidence indicates that immune mechanisms are central to disease initiation, progression, and plaque destabilization. Oxidized low-density lipoprotein (oxLDL) and related oxidation-specific epitopes (OSEs), ApoB100 peptides as well as newly identified autoantigens function as modified self-antigens that trigger both innate and adaptive immune responses, linking metabolic stress to chronic vascular inflammation. Innate immune activation is sustained through trained immunity, whereby monocytes and macrophages undergo long-lasting epigenetic and metabolic reprogramming that promotes a persistent pro-inflammatory phenotype. Additional contributors include dendritic cell-mediated antigen presentation, activation of the NLRP3 inflammasome and interleukin-1β signaling pathway, and type I interferon responses, all of which amplify vascular inflammation and plaque progression. Clinical benefits observed with anti-inflammatory therapies targeting these pathways provide evidence for their pathogenic relevance. Adaptive immune responses are characterized by the presence of antigen-experienced T and B lymphocytes within atherosclerotic lesions. oxLDL- and apolipoprotein B (ApoB)-reactive T cells contribute to disease progression through loss of immune tolerance and predominance of pro-inflammatory T helper 1 responses, whereas regulatory T cells exert protective effects. CD8 cytotoxic T cells as well as B cell subsets contribute to the formation of atherosclerotic plaque. Humoral responses against oxLDL generate both atheroprotective and pro-inflammatory antibodies, depending on their specificity and functional properties. Emerging evidence of tertiary lymphoid structures within the arterial wall further supports local antigen-driven immune activation. The accelerated development of atherosclerosis in systemic autoimmune diseases highlights important mechanistic overlap between systemic autoimmunity and vascular pathology. Nevertheless, immune activation in atherosclerosis remains largely initiated by lipid accumulation and vascular injury rather than a primary breakdown of systemic immune tolerance. Atherosclerosis does not appear to require a primary, generalized breakdown of systemic self-tolerance. Nevertheless, ApoB-reactive CD4+ T cells can lose regulatory features during disease progression, indicating impaired antigen-specific immune regulation. Whether, and to what extent, the local arterial environment drives this change remains to be established. Collectively, current evidence supports the concept that atherosclerosis is a chronic immune-mediated inflammatory disease with prominent autoimmune features, providing a rationale for the development of targeted immunomodulatory therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Academy of Athens, Section of Sciences, Chair of Medicine-Immunology, Athens, Greece.
- Departments of Physiology and Pathophysiology, School of Medicine, NKUA, Athens, Greece. Electronic address: kmauragan@med.uoa.gr.
Zitieren
APA
Moutsopoulos, H. M., & Mavragani, C. P. (2026). Is atherosclerosis an autoimmune disease?. Autoimmunity Reviews, 104232. https://doi.org/10.1016/j.autrev.2026.104232
Vancouver
Moutsopoulos HM, Mavragani CP. Is atherosclerosis an autoimmune disease?. Autoimmunity Reviews. 2026:104232. doi:10.1016/j.autrev.2026.104232
BibTeX
@article{Moutsopoulos2026,
author = {Moutsopoulos, Haralampos M and Mavragani, Clio P},
title = {Is atherosclerosis an autoimmune disease?},
journal = {Autoimmunity Reviews},
year = {2026},
pages = {104232},
doi = {10.1016/j.autrev.2026.104232}
}
EUVIMED